Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy

被引:6
|
作者
Shibasaki, Yuta [1 ]
Yokobori, Takehiko [2 ]
Sohda, Makoto [1 ]
Shioi, Ikuma [1 ]
Ozawa, Naoya [1 ]
Komine, Chika [1 ]
Suga, Kunihiko [1 ]
Nakazawa, Nobuhiro [1 ]
Osone, Katsuya [1 ]
Shiraishi, Takuya [1 ]
Okada, Takuhisa [1 ]
Sano, Akihiko [1 ]
Sakai, Makoto [1 ]
Ogawa, Hiroomi [1 ]
Kaira, Kyoichi [3 ]
Shirabe, Ken [1 ]
Saeki, Hiroshi [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi 3718510, Japan
[2] Gunma Univ Initiat Adv Res GIAR, Div Integrated Oncol Res, Maebashi 3718511, Japan
[3] Saitama Univ Hosp, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka 3501298, Japan
基金
日本学术振兴会;
关键词
L-type amino acid transporter-1; cancer aggressiveness; prognostic marker; chemosensitivity marker; TRANSPORTER; FLUOROURACIL; LEUCOVORIN; LEVAMISOLE; RESISTANCE; THERAPY; ASCT2;
D O I
10.3390/ijms24032604
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mammalian target of rapamycin (mTOR) is often activated in several cancers. We focused on two mTOR regulatory mechanisms: oxaliplatin-induced mTOR signaling and L-type amino acid transporter 1 (LAT1)-induced mTOR activation. High LAT1 expression in several cancers is associated with mTOR activation and resistance to chemotherapy. However, the significance of LAT1 has not yet been elucidated in colorectal cancer (CRC) patients treated with post-operative adjuvant chemotherapy. Immunohistochemistry was conducted to examine the significance of membrane LAT1 expression in 98 CRC patients who received adjuvant chemotherapy, including oxaliplatin. In vitro analysis was performed using CRC cell lines to determine the effects of LAT1 suppression on proliferation, oxaliplatin sensitivity, and mTOR signaling. LAT1 expression was associated with cancer aggressiveness and poor prognosis in 98 CRC patients treated with adjuvant chemotherapy. We found that positive LAT1 expression correlated with shorter survival in 43 patients treated with the capecitabine-plus-oxaliplatin (CAPOX) regimen. LAT1 suppression in CRC cells inhibited the proliferation potency and oxaliplatin-induced activation of mTOR signaling, and improved oxaliplatin sensitivity. LAT1 evaluation before adjuvant treatment may therefore be a sensitive marker for oxaliplatin-based regimens. Moreover, LAT1 may be a promising target for patients with refractory CRC.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer
    Han, Xiaohong
    Wang, Zheng
    Zhang, Lei
    Shen, Yinchen
    Tan, Qiaoyun
    Sun, Yongkun
    Wang, Jianfei
    Qian, Xiaoyan
    Yang, Hongying
    Shi, Yuankai
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (04): : 1522 - +
  • [2] Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
    Lee, Dae-Won
    Han, Sae-Won
    Cha, Yongjun
    Bae, Jeong Mo
    Kim, Hwang-Phill
    Lyu, Jaemyun
    Han, Hyojun
    Kim, Hyoki
    Jang, Hoon
    Bang, Duhee
    Won, Jae-Kyung
    Jeong, Seung-Yong
    Park, Kyu Joo
    Kang, Gyeong Hoon
    Kim, Tae-You
    BMC CANCER, 2019, 19 (1)
  • [3] Incidence of Cold-Induced Peripheral Neuropathy and Dose Modification of Adjuvant Oxaliplatin-Based Chemotherapy for Patients with Colorectal Cancer
    Altaf, Rahim
    Brixen, Annette Lund
    Kristensen, Bent
    Nielsen, Svend Erik
    ONCOLOGY, 2014, 87 (03) : 167 - 172
  • [4] Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy
    Sun, Xicai
    Yuan, Wei
    Hao, Furong
    Zhuang, Wenzhen
    MEDICAL SCIENCE MONITOR, 2017, 23 : 5389 - 5395
  • [5] Role of Calcium/Magnesium Infusion in Oxaliplatin-Based Chemotherapy for Colorectal Cancer Patients
    Kurniali, Peter C.
    Luo, Lu Guang
    Weitberg, Alan B.
    ONCOLOGY-NEW YORK, 2010, 24 (03): : 289 - 292
  • [6] p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Oh, Hyeon Jeong
    Bae, Jeong Mo
    Wen, Xianyu
    Jung, Seorin
    Kim, Younghoon
    Kim, Kyung Ju
    Cho, Nam-Yun
    Kim, Jung Ho
    Han, Sae-Won
    Kim, Tae-You
    Kang, Gyeong Hoon
    BRITISH JOURNAL OF CANCER, 2019, 120 (08) : 797 - 805
  • [7] Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy
    Park, Hanla A.
    Seibold, Petra
    Edelmann, Dominic
    Benner, Axel
    Canzian, Federico
    Alwers, Elizabeth
    Jansen, Lina
    Schneider, Martin
    Hoffmeister, Michael
    Brenner, Hermann
    Chang-Claude, Jenny
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (02) : 352 - 361
  • [8] Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer
    Li, Shuwei
    Xu, Kaili
    Gu, Dongying
    He, Lei
    Xie, Lisheng
    Chen, Zhengxin
    Fan, Zhimin
    Zhu, Lingjun
    Du, Mulong
    Chu, Haiyan
    Zhang, Zhengdong
    Wu, Yuan
    Ni, Min
    Wang, Meilin
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (11) : 939 - 949
  • [9] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Pare-Brunet, L.
    Sebio, A.
    Salazar, J.
    Berenguer-Llergo, A.
    Rio, E.
    Barnadas, A.
    Baiget, M.
    Paez, D.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (05): : 397 - 404
  • [10] Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy
    Huang, Ching-Wen
    Ma, Cheng-Jen
    Su, Wei-Chih
    Chen, Yi-Ting
    Tsai, Hsiang-Lin
    Yeh, Yung-Sung
    Chang, Tsung-Kun
    Hsu, Wen-Hung
    Yu, Fang-Jung
    Wang, Jaw-Yuan
    ONCOLOGY RESEARCH, 2020, 28 (7-8) : 701 - 714